BMO Capital analyst John McNulty maintained a Buy rating on Chemours Company (CC – Research Report) yesterday and set a price target of $27.00.

BMO Capital lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $45 from $60 and keeps a Market Perform rating on the shares.

Ameren (NYSE:AEE – Get Free Report) had its target price lifted by research analysts at BMO Capital Markets from $100.00 to ...

Net lease REIT W. P. Carey (NYSE:WPC) was upgraded at BMO Capital Markets on factors such as growth and incremental cost of capital.

Biogen (NASDAQ:BIIB – Free Report) had its price target decreased by BMO Capital Markets from $156.00 to $139.00 in a report ...

Fintel reports that on February 11, 2025, BMO Capital downgraded their outlook for Fluence Energy (NasdaqGS:FLNC) from ...

This is attributed to growing investor interest in the company's Alpha-1 Antitrypsin Deficiency (AATD) program. Analysts at BMO Capital estimate ... analysis of BEAM's investment potential ...

B2Gold (TSX: BTO) has upped its investment in Founders Metals (TSXV: FDR) to maintain its 5% shareholding, in response to the ...

Bank of Montreal’s main claim to fame is its thriving US business. BMO’s US segment includes 1,000 branches- – more than the ...

Tuesday, BMO Capital Markets highlighted the potential risks faced by Real Estate Investment Trusts (REITs ... with FMAP funding changes for the company. InvestingPro analysis shows VTR maintains ...